Kornimate/medical-research-clean huggingface dataset:
intraoperative ketamine for patients undergoing total joint arthroplasty

Conditions: Pain, Postoperative; Arthroplasty Complications

Summary: prospective randomized double blinded, placebo controlled study that will evaluate the effect of intra-operative ketamine administration on post-operative analgesic requirements and self-reported pain in patients undergoing total hip and total knee arthroplasty who demonstrate high levels of pain catastrophizing.

pain management can be one of the most challenging aspects of care for total joint arthroplasty patients. poor post-operative pain control can lead to poor patient satisfaction and functional outcomes. moreover, prolonged post-operative opioid utilization for post-operative pain is associated with substantial adverse sequelae. identifying patients at high risk for poor post-operative pain control, and implementing strategies to improve pain management in this population is of utmost importance. one patient feature that has been shown to reliably predict poor post-operative pain management is pain catastrophizing. currently available self-reported metrics such as the pain catastrophizing scale allow for pre-operative identification of patients who exhibit high levels of pain catastrophizing. furthermore, there currently exist strategies which may effectively improve post-operative pain management in this population. one such strategy is "pre-emptive" analgesia utilizing ketamine administered at the time of surgery. ketamine is commonly utilized in the treatment of both acute and chronic pain, and is believed to reduce pain intensity through a complex mechanism involving opioid receptors and excitatory neurotransmitters. it has been utilized in a variety of surgical procedures and has consistently been shown to reduce acute post-operative pain and analgesic consumption as long as 6 months after surgery, without a significant incidence of medication related side effects. to date, no study has evaluated the use of ketamine for total joint arthroplasty patients who demonstrate high levels of pain catastrophizing. we aim to study the effect of intra-operative ketamine administration on post-operative analgesic requirements and self-reported pain in patients undergoing total hip and total knee arthroplasty who demonstrate high levels of pain catastrophizing.

Eligibility criteria:
inclusion criteria: • adults, 18 years and older, undergoing primary total hip arthroplasty or total knee arthroplasty exclusion criteria: * history of intolerance or allergy to ketamine, either documented or self-reported. * history of increased intra-ocular pressure, uncontrolled hypertension, increased intra-cranial pressure, psychosis. * unable to provide consent. * current incarceration. * pregnant or breast feeding

Keywords: ketamine total hip replacement total knee replacement pain catastrophizing
custom made plate in orthognathic surgery

Conditions: Maxillary Prognathism; Maxillary Retrusion

Summary: orthognathic surgery has traditionally been used to correct dentofacial deformities. conventional methods rely on 2d radiographic images, occlusal splints, and dental casts, but these approaches have limitations, such as errors during face-bow transfer. technological advancements, including 3d imaging, virtual surgical planning (vsp), and computer-aided design and manufacturing (cad/cam), have improved the precision and outcomes of orthognathic surgery.

this study included one group of patients need orthognathic surgery and fixation of maxilla using custom made plate designed by 3d virtual planning using materialize mimic soft ware

Eligibility criteria:
inclusion criteria: * patients with skeletal class ii or class iii who need orthognathic surgery. * patients who suffer from clinical facial asymmetry. * patients with occlusal plane canting. * age range of patients 18-40 years old, with no gender prediction, able to read and sign the informed consent. exclusion criteria: * maxillofacial trauma * patients who suffer from maxillofacial tumors * segmental maxillary surgery. * oral soft tissues defects, infections and bone metabolism disturbance. * allergy to titanium implant. * patient with systemic disease and immunocompromised patient.

Keywords: orthognathic surgery virtual planning custom made plate
[18f]pi-2620 phase 3 histopathological study

Conditions: Alzheimer Disease

Summary: this study is an open-label, multi-center, non-randomized pivotal phase 3 study to assess the efficacy and safety of pet imaging with \[18f\]pi-2620 for detection of tau deposition in subjects with alzheimer's disease (ad) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.


Eligibility criteria:
inclusion criteria: only subjects who meet all of the following criteria will be eligible for enrollment into the study: 1. males and females aged 50 years and over 2. have a projected life expectancy of ≤ 1 year as determined by the investigator (terminal medical condition including but not limited to end-stage dementia, end-stage congestive heart failure, end-stage chronic obstructive pulmonary disease (copd), or end-stage cancer) 3. written informed consent obtained from the subject and/or the subject's legally authorized representative (lar), as applicable, to consent for study procedures and brain donation (consent consistent with the legal requirements of the state in which the subject dies) 4. can tolerate study procedures including lying down in pet scanner. the investigator will carefully assess each subject and use medical judgment to determine whether the subject can tolerate the imaging procedure exclusion criteria: subjects will be excluded from the enrollment if they: 1. are receiving aggressive treatment with life sustaining measures (e.g. receiving chemotherapy; palliative chemotherapy is allowed) 2. are known to have a structural brain lesion that would interfere either with pet imaging or pathological assessment (e.g. lesions are typically \> 2 cm at their greatest extent and may include stroke, primary or metastatic neoplasm, other tumors or cystic lesions. subjects with a history of major stroke or traumatic brain injury or other structural lesion as well as cases with a history of primary central nervous system (cns) neoplasm or known metastatic cancer must be discussed with the study sponsor prior to enrollment) 3. have suspected encephalopathy due to alcoholism or end-stage liver disease 4. are known to have a glomerular filtration rate below \< 15 ml/min 5. have received an investigational or approved therapy directly targeting amyloid or tau 6. are females of childbearing potential who are pregnant, lactating or breastfeeding, or who are not using adequate contraception 7. have implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, cns aneurysm clips and other medical implants that have not been certified for mri, or history of claustrophobia in mri (in case an mri is planned to be performed)
ancillary longitudinal csf collection study in the harvard biomarker study - hbs2

Conditions: Parkinson's Disease

Summary: the harvard biomarker study is a harvard-wide, longitudinal case-control study designed for discovering, replicating, and developing biomarkers for parkinson's disease and alzheimer's disease. high-quality biosamples and high-resolution clinical phenotypes are tracked at three visits over a two-year period for more than 2,000 individuals with early-stage pd, mci/ad, and controls without neurologic disease. the present "ancillary longitudinal csf collection study (short hbs2)" is an ancillary study to the parent harvard biomarker study. hbs2 is funded by the ninds. in hbs2, 75 participants are more intensely studied and followed over a three-year time period. clinical data and blood biospecimens are collected every six months and four annual csf collections are performed. biospecimens and clinical data are deposited into the ninds pd biomarkers program (pdbp) repository and the data management resource (dmr) and are accessible through the pdbp dmr website.


Eligibility criteria:
inclusion criteria for cases with pd: * age ≥ 21 * uk parkinson's disease society brain bank criteria or movement disorder specialist diagnosis of pd * hoehn \& yahr stage ≤ 3.0 * mini mental state exam score \>21 or authorized legal guardian available to sign consent * able to provide informed consent inclusion criteria for controls: * age ≥ 21 * absence of any neurological disease * no family history of a first-degree relative with pd * mini mental state exam score \>21 or authorized legal guardian available to sign consent * able to provide informed consent exclusion criteria for cases and controls: * acquired or inherited bleeding disorders * hematologic malignancies * hematocrit \< 30 * active ulcer or active colitis * known pregnancy * clinical contraindications to lumbar puncture (including: known mass lesion of the cns or evidence for raised intracranial pressure on fundoscopic exam; abnormal coagulation tests; platelet count \< 50,000; subject on warfarin (coumadin), heparin, dabigatran, rivaroxiban or apixaban; subject on both aspirin and clopidogrel (plavix); infection near the lp site or spinal deformity; known allergy to lidocaine)
study of chronic fatigue, depression, and anxiety among hypothyroid patients attending assuit university hospitals

Conditions: Hypothyroidism Primary

Summary: * assessment of the prevalence of chronic fatigue, depression, and anxiety among patients with hypothyroidism in assuit university hospital. * assess the severity of chronic fatigue, depression, and anxiety according to the duration and control of treatment in patients with hypothyroidism.

hypothyroidism is a prevalent endocrine illness with a global impact, necessitating treatment in extreme instances. inadequate management of hypothyroidism has been associated with adverse health outcomes, including neurological and musculoskeletal issues,this condition impacting approximately 1-6% of the general population. thyroid hormone is essential for the normal development of many human tissues and regulates the metabolism of virtually all cells and organs of the human body throughout life. overt hypothyroidism is defined by thyroid-stimulating hormone (tsh) levels above the upper limit of the reference range, while levels of free thyroxine (ft4) are below the lower limit of the reference range. the reference range is typically statistically defined by the 2.5th and 97.5th percentiles of the measured circulating thyroid hormone values in populations defined as healthy. it has been reported that up to one-third of patients presenting with fatigue have thyroid disease, predominantly in women,and fatigue was the most common noted symptom among patients with hypothyroidism.also patients with thyroid disorders are more prone to developing depressive symptoms. there are few previous studies that addressed this topic in the egyptian population.

Eligibility criteria:
inclusion criteria: * patients diagnosed with primary hypothyroidism. * age from 18 to 60 years. exclusion criteria: * patients who were previously diagnosed with any psychiatric diseases. * serious and chronic diseases (e.g. anemia, liver, heart or kidney problems). * consumption of medications that may interfere with thyroid function (e.g., chemotherapy), patients who had a history of any type of cancer, due to the confounding effects of cancer on fatigue as the outcome of interest. * women who were pregnant or had given birth in the last 6 months to exclude postpartum thyroiditis and depression.

Keywords: fatigue depression anxiety
the effects of ethyl-alpha-guanido-methyl ethanoate on skin reactions from glatiramer acetate injections

Conditions: Multiple Sclerosis

Summary: participants with multiple sclerosis that are currently treated with glatiramer acetate (ga, copaxone®) injections and have redness, pain, swelling, itching or a lump at the injection site will be recruited to examine histamine response of three topical treatments to reduce these symptoms.

participants are asked to be in this study because they have multiple sclerosis, are currently treated with glatiramer acetate (ga, copaxone®) injections and have redness, pain, swelling, itching or a lump at the injection site. the purpose of this study is to determine if the use of ethyl-a-guanida-methyl ethanoate (agee) will decrease histamine response measured by redness, swelling, and itch response following subcutaneous injection of glatiramer acetate (ga) for the treatment of multiple sclerosis (ms).

Eligibility criteria:
inclusion criteria: * able to give informed consent * between ages 19-65 * laboratory supported diagnosis of multiple sclerosis * currently treated with injectable ga, experiencing wheal and flare after injection exclusion criteria: * unable to give informed consent * treated with any other therapy for multiple sclerosis

Keywords: multiple sclerosis agee histamine response
rgb(red- green-blue) measurement of the nasal mucosal image

Conditions: Allergic Rhinitis

Summary: the aim of this study was to evaluate the color values of the nasal mucosa, which is easily assessable by a direct, non-invasive, objective photographic measurement, for the purpose of presenting a diagnostic objective parameter of allergic rhinitis (ar). all patients and controls were examined by the same 4 mm 0⁰endoscope and light source, and all endoscopic photographs of the septum and both inferior turbinates were taken. adobe photoshop elements 7.0 program was used to measure the numerical values of the red-green-blue (rgb) color components in endoscopic photographs of the nasal mucosa on the septum and inferior turbinates.

this study enrolled 73 patients with ar (group 1) and 73 normal healthy individuals(group 2) with no nasal pathologies and respiratory tract infection attending to the outpatient clinic of the tertiary referral center. patient's symptoms were questioned and noted by using lebel symptom score scale. clinical examination was also done to help diagnose and exclude acute respiratory tract infection. all of the patients had positive skin prick test results for at least one of the most common aeroallergens. all patients and controls were examined by the same 4 mm 0⁰endoscope and light source, and all endoscopic photographs of the septum and both inferior turbinates were taken. each image was marked with standardized points at the anterior part of the nasal mucosa on both sides (2 points each right and left sides of the anterior septum and 2 points each anterior part of the inferior turbinates). these points were numbered 1 and 2 over the right inferior turbinate; 3 and 4 over the right side of the anterior septum; 4 and 5 over the left inferior turbinate; 6 and 7 over the left side of the anterior septum. adobe photoshop elements 7.0 program was used to measure the numerical values of the red-green-blue color components in endoscopic photographs of the nasal mucosa on the septum and inferior turbinates.

Eligibility criteria:
inclusion criteria: * subject has positive skin prick test results * subject has more than 5 points of lebel symptom score scale * subjects between 18-60 ages * subjects with allergic rhinitis exclusion criteria: * negative skin prick test results * acute respiratory tract infection existence * scores less than 5 points of lebel symptom score scale

Keywords: rgb red-green-blue rhinitis allergic rhinitis nasal mucosa
simulator based powered mobility training of children with special needs

Conditions: Cerebral Palsy

Summary: this study compared conventional powered mobility practice to simulator based practice of children with special needs aged 6-18 years.

this study compared conventional powered mobility practice to simulator based practice of children with special needs aged 6-18 years. the study has 3 stages: 1) simulator validity study 2) powered mobility outcome measures reliability and validity for children 6-18 years 3) intervention study to compare simulator based practice and powered mobility practice. 1. simulator validity study included 30 children aged 6-18 years, proficient powered mobility drivers. all participants had physical disabilities- cp or neuromuscular conditions. 2. this stage included the first 30 children from the intervention study. data for the study was based on the first evaluation out of the two evaluations in the study. 3. this stage included 36 children aged 6-18 years in need of powered mobility practice to become a proficient driver. the particpants were divided into two groups- experimental (simulator based practice) and control group (standard powered wheelchair practice).

Eligibility criteria:
inclusion criteria: * children with a physical disability that are not proficient powered mobility driver * children that can use a joystick exclusion criteria: * children with visual accuracy limitations that cannot be corrected with glasses or contact lens; * children who have a severe intellectual and developmental disability as defined by the israel ministry of welfare's index for intellectual and developmental disabilities and reported by parents; children that have a unstable medical conditions that prevent them from participating in powered mobility training (e.g., epilepsy) * children that can operate a powered wheelchair via switches or a scanning device.

Keywords: powered mobility simulator powered mobility outcome measures
survival and 30-days hospital outcome in covid-19 patients in upper egypt

Conditions: Covid19; Coronavirus Disease; SARS-CoV-2

Summary: through history, there have been plenty of pandemics however; the social response to corona virus disease (covid-19) is unparalleled. it is assessed that almost four billion individuals are living in social segregation during this mother of all pandemics. initially described in china in december 2019, severe acute respiratory syndrome caused by corona virus 2 (sars-cov-2) has spread all over the world and by 18th july 2020- there was an emergent figure of 13,824,739 confirmed cases and 591.666 losses reported to the who. to date, egypt reported slightly over 82,000 confirmed covid-19 cases with 3858 deaths. the new pandemic is injuring not only health organizations of several countries but also the financial prudence universal. defining the clinical features and associated outcomes of patients diagnosed with coronavirus disease (covid-19) is fundamental to improving our understanding and adequate management of this illness. several articles have recently been published, describing the clinical features and outcomes of retrospective individuals with covid-19


Eligibility criteria:
inclusion criteria: * this study included 1064 patients consecutively admitted to isolation hospitals in upper egypt during the period from 22 march to 23 june 2020 exclusion criteria: * only hospitalized confirmed cases of covid-19 were included.

Keywords: covid-19 survival 30- days hospital outcome outcome
treatment of bipolar mania in older adults

Conditions: Bipolar Disorder; Mania

Summary: this study will compare the benefits and side effects of lithium and divalproex in the treatment of older adults with bipolar mania.

this is the first controlled acute treatment study of bipolar disorder in adults 60 years or older with current dsm-iv manic, mixed, or hypomanic episodes. the number of older adults with severe and disabling bipolar disorder is increasing, and information to guide the management of the treatment of the disease is lacking in this population. guidelines for treatment of younger people with bipolar disorder cannot be used for older people, and there are no safety and efficacy data upon which to base initial treatment decisions for older patients with bipolar mania. mood stabilizers (lithium and divalproex) are the first-line treatment for bipolar disorder. however, in aged patients physiological changes and comorbid diseases may increase vulnerability to side effects and limit the benefits of the medications. this double-blind study will compare the benefits and side-effects of 9 weeks of treatment with lithium and divalproex in people with bipolar mania. participants, who may be treated during inpatient hospitalization or as outpatients, will be randomly assigned to receive either lithium or divalproex. during the first 3 weeks of treatment careful titration of lithium and divalproex will be done to reach dose ranges. all other psychotropic medications will be discontinued. behavioral interventions and/or lorazepam may be added, if necessary. after the first 3 weeks, if symptoms do not improve, risperidone will be added to be taken everyday with the study medication.

Eligibility criteria:
inclusion criteria: * diagnosis of dsm-iv bipolar disorder, type i: current manic, mixed, or hypomanic episodes exclusion criteria: * rapid cycling bipolar disorder * history of substance abuse or dependence within last 3 months * diagnosis of schizophrenia or other chronic psychotic conditions * acute or unstable medical illness * documented intolerance to lithium, depakote, risperidone, or lorazepam * dementia * inability to communicate in english
comparison of the radiofrequency treatments for the treatment of trigeminal neuralgia.

Conditions: Trigeminal Neuralgia

Summary: the aim of this study is to compare the efficacy of radiofrequency of the gasserian ganglion versus peripheral branches of the trigeminal nerve for the treatment of trigeminal neuralgia.

trigeminal neuralgia (tn) is defined as sudden, severe, short-term, stabbing and recurrent pain in the distribution of one or more branches of the trigeminal nerve. many invasive treatments are available for patients who respond poorly to medical therapy. among them, radiofrequency therapy is a viable option with a reliable initial and long-term clinical efficacy.

Eligibility criteria:
inclusion criteria: * diagnosed with primary trigeminal neuralgia meets the criteria of the international classification of headache disorders. * suffering from severe trigeminal neuralgia that cannot be alleviated effectively with conservative therapy. * agree to participate in the study exclusion criteria: * infection at the puncture site. * coagulation disorder. * abnormal blood test (hepatic or renal function) * history of receiving invasive treatment (glycerol rhizolysis, radiofrequency thermocoagulation, balloon compression, gamma knife treatment, microvascular decompression)
dignity therapy for patients with early dementia and their family

Conditions: Dementia, Mild; Depressive Disorder

Summary: developed by harvey m. chochinov in 2005, dignity therapy (dt) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share. dt has shown to improve quality of life and a sense of dignity, as well as supporting relatives in the process of grievance. featuring a gradual loss of memories of the past, decline of cognitive functions and awareness of self, dementia can be regarded as a life-limiting or life-changing illness, which is often accompanied by significant psychological stress. dt may help patients and their relatives reduce this stress. yet, no studies have been conducted to determine the benefits of dt in patients with early stage dementia (esd). this study investigates the feasibility and acceptance of dt by patients with (very) mild dementia (cdr: 0.5 - 1.5) and their relatives, as well as their overall satisfaction. this study further seeks to determine the effects of dt on sense of dignity, quality of life, dyadic coping, and levels of anxiety and depression in a randomized controlled design.


Eligibility criteria:
inclusion criteria: * signed informed consent * diagnosis of very mild dementia * older 18 years of age * study partner (life partner, relative, close friend) available exclusion criteria: * unable to speak and read german * physical or cognitive incapacity to participate

Keywords: psychotherapy dignity family